Affordable Access

deepdyve-link
Publisher Website

Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?

Authors
  • Salado-Manzano, Cristina1, 2, 3, 4, 5
  • Perpiña, Unai1, 2, 3, 4, 5
  • Straccia, Marco6
  • Molina-Ruiz, Francisco J1, 2, 3, 4, 5
  • Cozzi, Emanuele7, 8
  • Rosser, Anne E9, 10, 11
  • Canals, Josep M1, 2, 3, 4, 5
  • 1 Laboratory of Stem Cells and Regenerative Medicine, Department of Biomedicine, University of Barcelona, Barcelona, Spain. , (Spain)
  • 2 Production and Validation Center of Advanced Therapies (Creatio), Faculty of Medicine and Health Science, University of Barcelona, Barcelona, Spain. , (Spain)
  • 3 Institute of Neurosciences, University of Barcelona, Barcelona, Spain. , (Spain)
  • 4 Networked Biomedical Research Centre for Neurodegenerative Disorders (CIBERNED), Barcelona, Spain. , (Spain)
  • 5 August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. , (Spain)
  • 6 FRESCI by SCIENCE&STRATEGY SL, Barcelona, Spain. , (Spain)
  • 7 Department of Cardio-Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. , (Italy)
  • 8 Transplant Immunology Unit, Padua University Hospital, Padua, Italy. , (Italy)
  • 9 Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom. , (United Kingdom)
  • 10 MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom. , (United Kingdom)
  • 11 Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United Kingdom. , (United Kingdom)
Type
Published Article
Journal
Frontiers in Cellular Neuroscience
Publisher
Frontiers Media SA
Publication Date
Jan 01, 2020
Volume
14
Pages
250–250
Identifiers
DOI: 10.3389/fncel.2020.00250
PMID: 32848630
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Neurodegenerative disorders such as Parkinson's (PD) and Huntington's disease (HD) are characterized by a selective detrimental impact on neurons in a specific brain area. Currently, these diseases have no cures, although some promising trials of therapies that may be able to slow the loss of brain cells are underway. Cell therapy is distinguished by its potential to replace cells to compensate for those lost to the degenerative process and has shown a great potential to replace degenerated neurons in animal models and in clinical trials in PD and HD patients. Fetal-derived neural progenitor cells, embryonic stem cells or induced pluripotent stem cells are the main cell sources that have been tested in cell therapy approaches. Furthermore, new strategies are emerging, such as the use of adult stem cells, encapsulated cell lines releasing trophic factors or cell-free products, containing an enriched secretome, which have shown beneficial preclinical outcomes. One of the major challenges for these potential new treatments is to overcome the host immune response to the transplanted cells. Immune rejection can cause significant alterations in transplanted and endogenous tissue and requires immunosuppressive drugs that may produce adverse effects. T-, B-lymphocytes and microglia have been recognized as the main effectors in striatal graft rejection. This review aims to summarize the preclinical and clinical studies of cell therapies in PD and HD. In addition, the precautions and strategies to ensure the highest quality of cell grafts, the lowest risk during transplantation and the reduction of a possible immune rejection will be outlined. Altogether, the wide-ranging possibilities of advanced therapy medicinal products (ATMPs) could make therapeutic treatment of these incurable diseases possible in the near future. Copyright © 2020 Salado-Manzano, Perpiña, Straccia, Molina-Ruiz, Cozzi, Rosser and Canals.

Report this publication

Statistics

Seen <100 times